"Lovenox – lost approximately half of US revenues to generic, CFO expects to retain this level (approx 50% of revenues) going forwards.:
This seems to suggest that the SNY CFO doesn't think Teva (or anyone besides Momenta/Sandoz) will enter the market. Maybe it was him that told Dew that t-enox was from ItalFarmaco. ;>)
Market Data 
Markets 
AI
